Garry Tobin is an Endocrinology/Metabolic physician affiliated with Washington University in St. Louis. OpenAlex indexes 25 publications with 683 citations (h-index 14); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Endocrinology, Ste 13b
Saint Louis, MO 631101032
Telephone
314-362-3500Provider last certified this registry record 19 Jan 2022.
Clinical trials
- Diabetes/ Endocrine Surveillance in SDS
Sponsor: Washington University School of Medicine
- Intensive Case Diabetes Management (ICDM) to Prevent Readmission
Sponsor: Washington University School of Medicine
- Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- Novo Nordisk IncProgram year20213 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
82.6%GLP-1 receptor agonist26.3%Trulicity43%Ozempic38%Victoza 3-Pak20%Part D<11 patientsSGLT2 inhibitor21.6%Farxiga65%Jardiance35%Part D<11 patients+ 3 more classes in this area
Hormonal (systemic)
11.7%l-Thyroxine11.7%Levothyroxine Sodium100%Part D≥15 patientsCardiovascular
5.6%Peroxisome Proliferator-activated Receptor alpha Agonist5.6%Gemfibrozil100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effect of a glucagon receptor antibody (REMD‐477) in type 1 diabetes: A randomized controlled trial
Diabetes Obesity and Metabolism
2017 - A Systematic Approach for the Prevention and Reduction of Hypoglycemia in Hospitalized Patients
Current Diabetes Reports
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”